Successful treatment of rhinocerebral zygomycosis using liposomal nystatin | Canada Hyperbarics Skip to main content
Case Report Leuk Lymphoma 2001

Successful treatment of rhinocerebral zygomycosis using liposomal nystatin

Mileshkin L, Slavin M, Seymour J, McKenzie A — Leuk Lymphoma, 2001

Tier 2, Indexed

Automatically imported from PubMed based on relevance criteria.

Summary

What Researchers Did

Researchers reported on the successful treatment of a single patient with a severe fungal infection of the nose and brain, who also had multiple myeloma.

What They Found

The patient, who had both multiple myeloma and a severe fungal infection called rhinocerebral mucormycosis, was successfully treated. The treatment involved a combination of therapies, including liposomal amphotericin, hyperbaric oxygen (HBOT), GM-CSF, and liposomal nystatin.

Canadian Relevance

No direct Canadian connection identified.

Study Limitations

As a case report, this study describes the experience of only one patient, meaning its findings cannot be broadly applied to all patients with similar conditions.

This plain-language summary is generated with AI assistance and checked against the source abstract before publication. See our editorial policy.

Was this summary helpful?

Study Details

Study Type Case Report
Category Aging & Longevity
Source Pubmed
PubMed ID 11697631
Year Published 2001
Journal Leuk Lymphoma
MeSH Terms Drug Carriers; Female; Humans; Liposomes; Magnetic Resonance Imaging; Middle Aged; Multiple Myeloma; Nose Diseases; Nystatin; Orbital Diseases; Treatment Outcome; Zygomycosis

Cite This Study

Share

Find a Canadian Clinic

Browse verified hyperbaric facilities across Canada.

View Canadian Facilities

Disclaimer: This study summary is provided for informational and educational purposes only. It does not constitute medical advice. The information presented reflects the findings of the original research authors and may not represent the views of Canada Hyperbarics. Always consult a qualified healthcare professional before making treatment decisions.

Last reviewed: April 17, 2026 | Reviewed by: Canada Hyperbarics Editorial Team | Editorial process | Research sources | Counts & methodology